Xeris Biopharma Reports Record Revenue for Q4 and Full Year 2025; Provides 2026 Guidance

Key Highlights from the Latest Financial Report

• Record Revenue: Xeris Biopharma Holdings, Inc. announced record total revenue for both the fourth quarter and full year 2025. Quarterly revenue hit \$86 million, while full-year revenue reached \$292 million.
• Profitability Turnaround: The company reported net income of \$11.1 million for Q4 2025, a dramatic improvement from a net loss of \$5.1 million in Q4 2024. For the full year, Xeris reduced its net loss to \$54.8 million, compared to a loss of \$54.8 million in the previous year.
• Adjusted EBITDA Surge: Adjusted EBITDA for Q4 was \$25.1 million, up \$16.8 million year-over-year, signaling strong operational leverage and improved cost management.
• Balance Sheet Strengthening: Total assets increased to \$383.5 million at year-end 2025, up from \$323.1 million at year-end 2024. Stockholders’ equity improved to \$13.7 million from a deficit of \$29.6 million.
• 2026 Guidance:
  • Total revenue expected between \$375 million and \$390 million.
  • Gross margin to improve modestly, reflecting favorable product mix.
  • Adjusted EBITDA expected to increase in absolute dollars compared to 2025.
• Upcoming Investor Events: Xeris management will participate in several major healthcare conferences in March 2026, including Leerink, Barclays, and Jefferies Biotech on the Beach Summit. These events may provide further insights or updates for investors.

Detailed Financial Performance

Quarterly Results:

• Q4 2025: Net income of \$11.1 million, Adjusted EBITDA of \$25.1 million, total revenue \$86 million.
• Q4 2024: Net loss of \$5.1 million, Adjusted EBITDA of \$8.3 million.

Annual Results:

• 2025: Revenue \$292 million, Net loss \$54.8 million, Adjusted EBITDA \$59.4 million.
• 2024: Revenue slightly lower, Net loss \$54.8 million, Adjusted EBITDA \$1.2 million.

Balance Sheet:

• Total assets: \$383.5 million (2025), up from \$323.1 million (2024).
• Total stockholders’ equity: \$13.7 million, improved from \$(29.6) million deficit.
• Current liabilities largely stable, payables at \$3.1 million.

Shareholder-Relevant and Potentially Price-Sensitive Information

• Profitability Milestone: Achieving net income in Q4 after prior losses could signal a turning point for Xeris, increasing investor confidence and potentially impacting share price positively.
• Strong 2026 Guidance: Management’s projection of revenue growth and gross margin improvement suggests continued strong performance, which is likely to be viewed favorably by the market.
• Balance Sheet Improvements: The shift from negative to positive equity is significant, reducing financial risk and improving the company’s standing for future financing or strategic investments.
• Ongoing Conference Participation: Multiple upcoming investor events present opportunities for further news or updates that could influence market perception and share price.
• Non-GAAP Metrics: The company continues to emphasize Adjusted EBITDA as a key measure, indicating operational improvements beyond GAAP results.

Other Notable Items

• No pre-commencement tender offers, written communications under Rule 425, or soliciting material under Rule 14a-12 were noted in this filing.
• Xeris is not an emerging growth company, which means it is subject to full SEC reporting requirements.

Potential Share Price Impact

The combination of record revenue, a return to quarterly profitability, positive full-year guidance, and strengthened balance sheet are all positive factors that could drive share price appreciation. Additionally, investor events in March may bring further visibility and news flow. Investors should monitor for updates at these conferences and review subsequent filings for additional developments.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All forward-looking statements are subject to risks and uncertainties as outlined in Xeris Biopharma’s filings with the SEC. Actual performance may differ materially from projections. Investors are advised to conduct their own due diligence and consult with a financial advisor before making investment decisions.

View Xeris Biopharma Holdings, Inc. Historical chart here